EPC

Analyst Note: EPC (Edgewell Personal Care Company)

Date: 2026-06-13 Current Price: $23.11

1. Structural Readiness

• State: Context-Only (No active technical setup identified in the provided data stream).
• Conservative Entry: —
• Breakout Level: —
• Extension: —
• ATR Current: 4.7% (High).

2. Thesis Layer

• Thesis Classification: TACTICAL / Setup-Led.
• Secular Exposure: No named secular thesis is active for this name as of this date.
• Judgment Criteria: The investment case must be judged strictly on the quality of the operational turnaround and the structural setup (once defined), rather than a macro secular tailwind. The company is currently in a post-divestiture restructuring phase, and the thesis is derived from the execution of management's transformation plan, not a broad market theme.

3. Business Overview

Edgewell Personal Care Company is a global manufacturer and marketer of personal care products, operating primarily in three segments: Wet Shave, Sun and Skin Care, and (historically) Feminine Care. As of the event date, the company has executed a major strategic pivot.

• Core Operations: The company markets leading brands including Schick, Wilkinson Sword, Edge, Skintimate, Banana Boat, Hawaiian Tropic, Jack Black, and Bulldog.
• Strategic Divestiture: On February 2, 2026, the company closed the transaction to sell its Feminine Care segment (brands: Playtex, Stayfree, Carefree) to Essity for approximately $340 million on a cash-free and debt-free basis. This divestiture was approved by the Board on November 6, 2025, to transform Edgewell into a more focused entity.
• Segment Performance (Fiscal 2026):
• Wet Shave: Represents approximately 60% of total sales. The company holds the number two global market share position in wet shaving. In the U.S., the company reported accelerating consumption growth and share gains, with value share increasing by approximately 50 basis points.
• Sun, Skin Care, and Grooming: These businesses combined are approaching 40% of total sales. Grooming specifically now accounts for over 10% of the business.
• Sales Trends: Organic net sales decreased by 2.4% (or $12.6 million) in the reported period. This decline was driven by a 4.8% organic sales decline in North America, primarily due to lower volumes in Wet Shave and Sun Care. However, International markets saw 1.0% organic growth, driven by volume in Wet Shave and favorable pricing.
• Customer Concentration: Walmart accounted for approximately 17.4% of net sales in fiscal 2025. Target represented 9.2% of the Sun and Skin Care segment and 10.1% of the Feminine Care segment.
• Supply Chain & Operations: The company is streamlining operations, including consolidating Mexico facilities and Wet Shave operations. This restructuring is expected to incur pre-tax charges of approximately $90 million in fiscal 2026.

4. Archetype and Conviction Stack

• Archetype: Margin Inflector / Restructuring Recovery.
• The company is transitioning from a diversified personal care conglomerate to a focused player in Wet Shave and Sun/Skin Care. The archetype is defined by the "inflection" of margins following the divestiture of the lower-margin or non-core Feminine Care segment and the realization of productivity savings.
• Management Expectations (Source: Earnings Transcript 2026-05-06):
• Margins: Management expects gross margin to expand in the second half of 2026, driven by pricing actions, tariff mitigation, and productivity initiatives reaching full run rate.
• Productivity: The company delivered 220 basis points of gross productivity savings in the quarter.
• Future Savings: Management expects to begin realizing savings in fiscal 2027, with a full run rate in fiscal 2028, equating to roughly 2 percentage points of company-wide gross margin improvement.
• Outlook: Adjusted EPS is expected to be in the range of $1.70 to $2.10. Adjusted EBITDA is expected to remain unchanged in the range of $245 million to $265 million. Organic net sales are expected to be down 1% to up 2%, excluding FX tailwinds.
• Valuation Context: The financial spine indicates a forward consensus EPS of $1.895 for FY1 and $2.056 for FY2.
• Conviction Stack:
• Thesis Strength: Moderate. The strategic focus is clear, but the near-term sales decline (4.8% in NA) presents a headwind.
• Evidence Quality: High. The evidence base is robust, containing specific earnings transcripts, SEC filings, and financial spine data.
• Structural Quality: The restructuring is well-documented, but the "inflection" point (margin expansion) is expected to materialize in H2 2026 and beyond.
• Rerating Potential: Dependent on the successful execution of the margin expansion plan and the stabilization of North American volumes.

5. Invalidations, Strengtheners, and Gaps

• Invalidation Factors:
• A sustained decline in Wet Shave market share or volume in North America beyond the current 4.8% decline.
• Failure to achieve the projected 220 basis points of productivity savings or the anticipated 2% margin improvement by fiscal 2028.
• Strengtheners:
• Confirmation of the 2% gross margin improvement trajectory in subsequent quarters.
• Acceleration of organic sales growth in North America, reversing the current decline.
• Successful integration of the post-divestiture capital structure and realization of the $340M proceeds.
• Gaps in Evidence:
• FX Impact: While FX is mentioned as a tailwind/offset, the specific magnitude of currency movements in the current quarter is not detailed beyond the 40 basis points of unfavorable movement in the prior period.
• Post-Divestiture Synergies: The specific timeline for the full realization of synergies from the consolidation of Mexico facilities is not quantified beyond the fiscal 2028 run rate.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key evidence: Management guidance for 2% gross margin improvement by fiscal 2028; successful $340M divestiture of Feminine Care segment; Wet Shave segment holding #2 global market share with 60% of total sales. Expected path: Management expects gross margin expansion in H2 2026 as productivity initiatives reach run rate, followed by further margin improvement in fiscal 2027 and 2028. Expected horizon: 12 to 24 months for the full realization of the margin inflection thesis. Failure mode to watch: A sustained close below the current price level combined with a failure to reverse the North American volume decline, signaling the restructuring is not gaining traction.